The latest clinical results detailing the persisting benefits of NeuroAiDTM in stroke recovery have been published in Cerebrovascular Diseases mid-April. These results have been presented at ESOC in Glasgow and ESC in Vienna.
Moleac has developed the first product that helps patients to recover faster and better from their stroke disabilities.
Moleac’s Multi-Modal Approach to Treatment for Brain Injuries
Advances in research in the field of brain injury, like stroke, trauma and global ischemia, has never been more exciting and encouraging for the prospect of discovering novel effective treatments.
The conventional approach to research in acute treatment to develop one molecule targeted at one specific process in the pathway of one particular disease has failed in many consecutive clinical trials. Moleac takes on a multi-model strategy in its approach to drug development.
What is Stroke?
Stroke is a devastating disease affecting 17 million victims worldwide. It is a leading cause of adult acquired disability in many countries. Stroke is a medical emergency. Do not wait! The longer a patient waits, the more damage happens to the brain. After a stroke, an estimated 2 million brain cells, called neurons, die every minute without treatment.
Moleac aims at becoming a leading destination of choice for both experienced executives looking for new perspectives and young, ambitious talents looking to pave their careers in an innovative, dynamic and international company.
If you are talented and ready for new challenges, discover what Moleac has to offer you.